Indication
Primary biliary cholangitis
Primary biliary cholangitis is a chronic autoimmune cholestatic liver disorder characterized by T-lymphocyte–mediated inflammation and gradual destruction of the small intrahepatic bile ducts. Read more about Primary biliary cholangitis
18 drugs 13 manufacturers
Drugs that treat it
Common Primary biliary cholangitis therapies.
URSO FORTE (ursodiol)
URSO (ursodiol)
URSODIOL
URSODIOL
URSODIOL
URSO 250 (ursodiol)
IQIRVO (elafibranor)
LIVDELZI (seladelpar lysine)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrimary biliary cholangitis is a chronic autoimmune cholestatic liver disorder characterized by T-lymphocyte–mediated inflammation and gradual destruction of the small intrahepatic bile ducts.
This progressive ductopenia impairs bile acid secretion, resulting in toxic intrahepatic cholestasis, chronic periportal inflammation, and downstream hepatic parenchymal damage.
The disease most commonly affects middle-aged women and is clinically characterized by elevated alkaline phosphatase, the presence of serum antimitochondrial antibodies, and presenting symptoms such as fatigue and pruritus.
Without intervention, sustained cholestasis and fibrogenesis can lead to advanced cirrhosis, portal hypertension, and end-stage liver failure.
- nih.gov
Primary biliary cholangitis is a chronic autoimmune cholestatic liver disorder characterized by T-lymphocyte–mediated inflammation and gradual destruction of the small intrahepatic bile ducts This progressive ductopenia impairs bile acid secretion, resulting in toxic intrahepatic cholestasis, chronic periportal inflammation, and downstream hepatic parenchymal damage The disease most commonly affects middle-aged women and is clinically characterized by elevated alkaline phosphatase, the presence ...
- nih.gov
Primary biliary cholangitis is a chronic autoimmune cholestatic liver disorder characterized by T-lymphocyte–mediated inflammation and gradual destruction of the small intrahepatic bile ducts
- nih.gov
This progressive ductopenia impairs bile acid secretion, resulting in toxic intrahepatic cholestasis, chronic periportal inflammation, and downstream hepatic parenchymal damage The disease most commonly affects middle-aged women and is clinically characterized by elevated alkaline phosphatase, the presence of serum antimitochondrial antibodies, and presenting symptoms such as fatigue and pruritus
- nih.gov
The disease most commonly affects middle-aged women and is clinically characterized by elevated alkaline phosphatase, the presence of serum antimitochondrial antibodies, and presenting symptoms such as fatigue and pruritus Without intervention, sustained cholestasis and fibrogenesis can lead to advanced cirrhosis, portal hypertension, and end-stage liver failure
- nih.gov
The disease most commonly affects middle-aged women and is clinically characterized by elevated alkaline phosphatase, the presence of serum antimitochondrial antibodies, and presenting symptoms such as fatigue and pruritus
Personalize your experience
Follow Primary biliary cholangitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.